Liver function test (LFT) abnormalities are often observed in patients with heart failure (HF). However, the relation of LFTs with outcomes has not been well described. Patients of the VA Palo Alto Health Care System (3 inpatient facilities and 7 community clinics) with a complete set of LFTs in the 60 days before a first HF diagnosis were included in the analysis from January 2005 to April 2013. A total of 2,096 patients met inclusion criteria. Patients were a mean of 71 ± 12 years old, 97% were men, 57% had a previous diagnosis of ischemic heart disease, and the mean left ventricular ejection fraction was 51 ± 12%. The median (twenty fifth and seventy fifth) values were albumin 3.6 g/dl (3.3, 3.9), alanine transaminase 21 IU/L (16, 30), aspartate transaminase 24 IU/L (20,31), AP 70 IU/L (57, 87), and total bilirubin 0.8 mg/dl (0.6, 1.0). There were 851 deaths (41%) over a mean duration of 41 ± 27 months. Mortality significantly increased with lower values of albumin and alanine transaminase and higher levels of aspartate transaminase and AP. The association with total bilirubin was not significant. In conclusion, many LFT values in the "normal" range are independently associated with decreased survival beyond traditional risk factors for mortality in HF.